

Clinical Practice Standard:
Naturopathic Medicine
Prescribing, Compounding and
Dispensing Drugs

Not in force until April 1, 2026



College of
**COMPLEMENTARY HEALTH
PROFESSIONALS OF BC**



| Principle | Outcome Statement |
|--|--|
| As a naturopathic medicine licensee, you must meet the following Principles within the Clinical Practice Standard: Naturopathic Medicine Prescribing, Compounding and Dispensing Drugs. | People receiving health services from a naturopathic physician licensee expect that their health care practitioner will: |
| Principle 1: Naturopathic medicine licensees must prescribe drugs in accordance with ethical, legal and professional standards | Prescribe drugs responsibly, adhering to applicable ethical guidelines, legal requirements, and professional standards to protect patient safety. |
| Principle 2: Naturopathic medicine licensees must dispense, compound and administer drugs in accordance with ethical, legal and professional standards. | Dispense, compound, and administer drugs responsibly, adhering to ethical guidelines, legal requirements, and professional standards to ensure patient safety and quality of care. |

Definitions

compound: means

- (a) with respect to a drug, to mix the drug with at least one other ingredient, and
- (b) in any other case, to mix 2 or more appropriate ingredients

dispense: with respect to a drug, includes:

- (a) to prepare and sell a drug referred to in a prescription,
- (b) to provide a drug to a person for the purpose of self-administration or administration to or by another person,
- (c) to take steps to ensure the pharmaceutical and therapeutic suitability of a drug for its intended use, and
- (d) to take steps to ensure a drug's proper use



drug: means a drug that is included or incorporated by reference under a Schedule;

- (a) a Schedule I drug of the *Drug Schedules Regulation*; that is not listed in the Appendix of the *Complementary Health Professionals Regulation*, or
- (b) a Schedule II drug of the *Drug Schedules Regulation*

point-of-care administration: immediate administration of medication as part of acute treatment at the time of care or as part of a therapeutic procedure performed by the licensee.

prescribe, with respect to a drug: means to issue a prescription.

prescription, with respect to a drug: has the same meaning as in the *Pharmacy Operations and Drug Scheduling Act*

Principle 1: Naturopathic medicine licensees must prescribe drugs in accordance with ethical, legal and professional standards.

To meet this standard, naturopathic medicine licensees must:

- 1.1 Hold current prescriptive authority certification with the College.
- 1.2 Prescribe:
 - 1.2.1 In accordance with the BC *Pharmacy Operations and Drug Scheduling Act* and the federal *Controlled Drugs and Substances Act* and associated regulations.
 - 1.2.2 As defined by the *Complementary Health Professionals Regulation* (the “Regulation”), including limits and conditions set out in the Regulation and in Appendix A to this Standard.
 - 1.2.3 Only drugs approved by Health Canada.
 - 1.2.4 Only with the appropriate knowledge, skills and competence.
- 1.3 Not prescribe drugs for themselves.



- 1.4 Not prescribe solely on mailed or faxed information, electronic questionnaire, or countersigning.
- 1.5 Not provide any person with a blank, signed prescription.
- 1.6 Prevent unauthorized use of prescription pads.
- 1.7 Obtain the best possible drug history for the patient, including the use of non-prescription drugs and natural health products, using PharmaNet and/or other sources.
- 1.8 Provide patients and/or their substitute decision makers with accurate, current, complete and evidence-based information about the proposed drug therapy sufficient to obtain informed consent.
- 1.9 Complete prescriptions including the following information:
 - 1.9.1 Date of issue
 - 1.9.2 Name and date of birth of the patient
 - 1.9.3 Name, strength and dosage form of the substance
 - 1.9.4 Quantity prescribed and quantity to be dispensed
 - 1.9.5 Directions for use, including frequency, interval or maximum daily dose, route of administration and duration of drug therapy
 - 1.9.6 Directions for number of allowable refills and interval between refills
 - 1.9.7 Licensee's name, address, telephone number and signature including unique naturopathic physician identifier/number
 - 1.9.8 Directions to the pharmacist not to renew or alter if a pharmacist-initiated adaptation is clinically inappropriate
- 1.10 When transmitting a prescription to a pharmacy, ensure that the prescription is sent:
 - 1.10.1 Securely and confidentially to the pharmacy of the patient's choice.
 - 1.10.2 Directly from the licensee's office or health institution of which the patient is under care, or from another location that could reasonably confirm the legitimacy of the prescription.



1.11 Actively engage in required provincial and/or national adverse reaction reporting programs.

Principle 2: Naturopathic medicine licensees must dispense, compound and administer drugs in accordance with ethical, legal and professional standards.

To meet this standard, naturopathic medicine licensees must:

2.1 Only-dispense drugs to their own patients for:

2.1.1 point-of-care administration,

2.1.2 drugs provided as pharmaceutical samples,

2.1.3 allergy serums.

2.3 Not dispense any botanical products or preparations that are drugs.

2.4 Only compound drugs for point of care administration.

2.5 Only compound, dispense, or administer immunoprophylactic agents which are identified by the BC Centre for Disease Control (BCCDC).

2.6 Meet all practice standards expected of a pharmacist as outlined in the *Pharmacy Operations and Drug Scheduling Act (PODSA)*, and all requirements outlined in federal legislation (*Food and Drugs Act, Controlled Drug and Substances Act*) when ordering, storing, and dispensing drugs to their patients including:

2.6.1 Proper storage, including cold-chain custody for temperature-sensitive drugs

2.6.2 Security

2.6.3 Labelling

2.6.4 Packaging

2.6.5 Counselling

2.6.6 Monitoring for drug interactions



- 2.6.7 Documentation
- 2.6.8 Record keeping
- 2.6.9 Inventory audits
- 2.6.10 Medication reconciliation
- 2.6.11 Accessing and recording information in PharmaNet when appropriate

Not in force until April 1, 2026

Appendix A:

Limits and Conditions

Not in force until April 1, 2026



College of
**COMPLEMENTARY HEALTH
PROFESSIONALS OF BC**



The following limits and conditions apply to naturopathic medicine licensees when prescribing compounding, dispensing or administering drugs:

1. Drugs listed in this Appendix are **excluded**.
2. Drugs listed in Schedule IA of the BC Drug Schedules Regulation or any schedule of the *Federal Controlled Drugs and Substances Act*, are **excluded**.
3. Any newly approved drug for use in Canada is automatically restricted and **excluded** until formally reviewed and authorized by the College.

Antibiotics with Narrow Therapeutic Range

No antibiotic may be administered in any parenteral form.¹

- Amikacin and its salts and derivatives
- Amphotericin B and its salts and derivatives
- Apramycin and its salts
- Aztreonam and its salts
- Bacitracin and its salts and derivatives (excluded for parenteral use only)
- Candicidin and its salts and derivatives
- Carbomycin and its salts and derivatives
- Caspofungin and its salts and derivatives
- Cefoperazone and its salts and derivatives
- Cilastatin and its salts
- Colistin and its salt and derivatives
- Dalfopristin and its salts
- Dihydrostreptomycin and its salts and derivatives
- Enrofloxacin
- Gentamicin (excluded for parenteral use only)
- Grepafloxacin and its salts and derivatives
- Hetacillin and its salts and derivatives
- Lefamulin for IV use
- Marbofloxacin and its salts and derivatives
- Mecillinam and its salts and derivatives
- Mezlocillin and its salts and derivatives
- Oxacillin and its salts and derivatives
- Quinupristin and its salts
- Streptomycin and its salts and derivatives
- Tazobactam and its salts and derivatives
- Tedizolid or its salts or derivatives (excluded for parenteral use only)
- Ticarcillin and its salts and derivatives
- Tigecycline
- Tobramycin and its salts and derivatives (excluded for parenteral use only)
- Trovafloxacin and its salts and derivatives

- Virginiamycin and its salts and derivatives

- Voriconazole



† No antibiotic may be administered in any parenteral form, with the exception of Ceftriaxone, Clindamycin, and Bicillin are approved for parenteral use by ND licensees of College, which are approved for parenteral use by ND licensees of the College for use in Lyme disease treatment.

Antiretroviral Agents

- | | | |
|--|--|--|
| <ul style="list-style-type: none"> • Abacavir • Atovaquone (excluded for treatment of HIV or infections resulting from HIV) • Bictegravir/emtricitabine/tenofovir alafenamide • Boceprevir • Cabotegravir | <ul style="list-style-type: none"> • Darunavir ethanolate • Darunavir/cobicistat/emtricitabine/tenofovir alafenamide • Dolutegravir or its salts • Doravirine • Elvitegravir • Entecavir • Etravirine and its salts | <ul style="list-style-type: none"> • Fosamprenavir calcium • Fostemsavir or its salts • Lenacapavir • Maraviroc • Raltegravir and its salts • Rilpivirine • Telbivudine |
|--|--|--|

Antiviral Agents

- | | | |
|--|---|---|
| <ul style="list-style-type: none"> • Asunaprevir • Daclatasvir or its salts • Dasabuvir or its salts • Elbasvir • Foscarnet sodium and its salts • Grazoprevir • Idoxuridine • Ledipasvir or its salts | <ul style="list-style-type: none"> • Letemovir or its salts • Maribavir and its salts • Methisazone • Ombitasvir • Paritaprevir (Veruprevir) • Peramivir or its salts or derivatives • Pibrentasvir • Ribavirin | <ul style="list-style-type: none"> • Simeprevir or its salts • Sofosbuvir/Velpatasvir • Tecovirimat • Telaprevir or its derivatives • Valganciclovir and its salts and derivatives • Velpatasvir • Voxilaprevir or its salts |
|--|---|---|



Antineoplastic Agents

- Abemaciclib
- Abiraterone
- Acalabrutinib
- Afatinib or its salts
- Alectinib
- Alpelisib
- Amivantamab
- Arsenic trioxide
- Asciminib and its salts
- Asparaginase (by injection)
- Atezolizumab
- Avapritinib or its salts
- Avelumab
- Axicabtagene ciloleucel
- Axitinib
- Azacitidine or its salts or derivatives
- Bendamustine
- Belzutifan
- Binimetinib or its salts
- Blinatumomab
- Bosutinib or its salts
- Brentuximab vedotin
- Brexucabtagene autoleucel
- Brigatinib
- Burosumab
- Cabozantinib
- Calaspargase pegol
- Capivasertib and its salts
- Capmatinib and its salts
- Carfilzomib
- Catumaxomab
- Cedazuridine and decitabine
- Cemiplimab
- Cenegermin
- Ceritinib or its salts
- Ciltacabtagene autoleucel
- Clofarabine
- Cobimetinib
- Crizotinib
- Dabrafenib mesylate
- Dacomitinib
- Daratumumab
- Darolutamide
- Dasatinib
- Decitabine
- Degarelix or its salts or derivatives
- Dinutuximab
- Dostarlimab
- Durvalumab
- Elotuzumab
- Elranatamab
- Enasidenib
- Encorafenib or its salts
- Enfortumab vedotin
- Entrectinib
- Enzalutamide
- Epcoritamab
- Erdafitinib
- Eribulin or its salts or derivatives
- Erlotinib & Salts
- Everolimus
- Fedratinib
- Epcoritamab
- 5-Fluorouracil (excluded for intravenous use)
- Fruquintinib or its salts
- Gemtuzumab ozogamicin
- Gilteritinib
- Glasdegib
- Glofitamab
- Guselkumab
- Ibrutinib or its salts
- Idelalisib
- Infigratinib or its salts
- Idecabtagene vicleucel
- Inavolisib or its salts
- Inotuzumab ozogamicin
- Ipilimumab
- Isatuximab
- Ivosidenib or its salts
- Ixazomib
- Lapatinib and Salts
- Larotrectinib
- Lenalidomide
- Lenvatinib or its salts
- Loncastuximab tesirine
- Lorlatinib
- Lurbinectedin or its salts or derivatives
- Lutetium vipivotide tetraxetan
- Midostaurin or its salts
- Mogamulizumab
- Necitumumab
- Nelarabine
- Neratinib
- Netupitant
- Nilotinib & Salts
- Niraparib
- Nivolumab
- Obinutuzumab
- Ofatumumab
- Olaparib
- Olaratumab
- Osimertinib
- Oxaliplatin
- Palbociclib

- Panitumumab
- Patisiran
- Pazopanib or its salts
- Pegaspargase
- Pembrolizumab
- Pemigatinib or its salts
- Pertuzumab
- Polatuzumab vedotin
- Pomalidomide or its salts
- Ponatinib or its salts
- Pralatrexate
- Pralsetinib or its salts
- Ramucirumab
- Regorafenib
- Relatimab
- Retifanlimab
- Ribociclib

- Ripretinib or its salts
- Ruxolitinib
- Sacituzumab govitecan
- Selinexor and its salts
- Selpercatinib and its salts
- Selumetinib and its salts
- Sonidegib
- Sorafenib or its salts
- Sotorasib
- Sunitinib and its salts
- Tafasitamab
- Talquetamab
- Talazoparib or its salts
- Tarlatamab
- Tebentafusp

- Teclistamab
- Tepotinib and its salts
- Tipiracil
- Tisagenlecleucel
- Trabectedin
- Trametinib
- Tremelimumab
- Tucatinib
- Vandetanib
- Vemurafenib
- Venetoclax
- Vindesine and its salts
- Vismodegib
- Vorasidenib or its salts
- Vorinostat
- Zanubrutinib and salts
- Zolbetuximab



Note Periwinkle alkaloids in naturopathic preparations are allowed but shall not be used as chemotherapeutic agents.

Anticonvulsants

- Brivaracetam
- Ethotoin and its salts
- Ezogabine
- Fosphenytoin and its salts
- Methoin (mephenytoin) and its salts
- Perampanel

- Phenacemide
- Rufinamide
- Stiripentol
- Trimethadion
- Vigabatrin and its salts and derivatives
- **The following agents are only**

allowed for the management of pain:

- Gabapentin and its salts and derivatives
- Pregabalin

Disease Modifying Agents

- Abatcept
- Asfotase alfa

- Barticinib
- Belimumab

- Dupilumab
- Eculizumab

- Efgartigimod alfa
- Exagamglogene autotemcel
- Golimumab
- Momelotinib or its salts
- Lebrikizumab
- Omalizumab
- Ranibizumab

- Rozanolixizumab
- Secukinumab
- Sotatercept
- Tocilizumab
- Tralokinumab
- Trofinetide or its salts
- Ustekinumab
- Vedolizumab

- **The following agent is allowed for chelation therapy purposes only:**
 - Penicillamine

Drugs Administered Intravenously

- Micafungin

Agents Primarily or Exclusively Used by Medical Specialists

- Abciximab
- Agalsidase beta
- Alglucosidase alfa
- Alpha1- proteinase inhibitor (human)
- Amifampridine
- Apremilast
- Anifrolumab
- Antihemophilic factor
- Antihemophilic/ von Willebrand factor
- Avacopan or its salts
- Avalglucosidase alfa
- Avermectin or its derivatives
- Bamlanivimab
- Belumosudil or its salts
- Benralizumab
- Berotralstat or its salts
- Brodalumab
- Brolucizumab
- Caplacizumab
- Canakinumab

- Cangrelor and its salts or derivatives
- Carglumic acid or its salts or derivatives
- Casirivimab
- Cerliponase alfa
- Certolizumab pegol
- Cidofovir
- Clevidipine or its salts
- Concizumab
- Cysteamine (Mercaptamine) or its salts
- Danicopan or its salts
- Daclizumab beta
- Deucravacitinib or its salts
- Difelikefalin or its salts
- Dimethyl fumarate
- Edaravone
- Efanesoctocog alfa (including but not limited to Recombinant

- coagulation factor VIII Fc - von Willebrand factor - XTEN fusion protein (rFVIII-Fc-VWF-XTEN))
- Elexacaftor or its salts
- Eliglustat or its salts
- Elosulfase alfa
- Eltrombopag or its salts
- Emicizumab
- Emamectin or its salts
- Eplerenone
- Eplontersen or its salts
- Epoprostenol sodium
- Esketamine
- Etomidate
- Fampridine
- Faricimab
- Finerenone and its salts
- Fingolimod
- Follitropin delta

- Fostamatinib
- Galsulfase
- Givosiran
- Glycerol phenylbutyrate
- Hemin
- Icatibant or its salts
- Idebenone
- Idursulfase
- Imdevimab
- Inotersen
- Iptacopan
- Isavuconazole
- Ivabradine
- Ivacaftor
- Ivacaftor/tezacaftor
- Ixekizumab
- Lanadelumab
- Lomitapide or its salts
- Lonoctocog alfa
- Lumacaftor/Ivacaftor
- Lumasiran and its salts
- Luspatercept
- Macitentan or its derivatives
- Mavacamten and its salts
- Mepolizumab
- Natalizumab
- Nesiritide or its salts
- Nintedanib or its salts
- Nitisinone
- Nusinersen
- Obiltoxaximab
- Ocrelizumab
- Onasemnogene
- Pasireotide or its salts
- Pegcetacoplan
- Pegvaliase
- PEGylated antihemophilic factor
- Phenylbutyric acid or its salts or derivatives
- Pirfenidone
- Plerixafor or its salts
- Polidocanol (injection)
- Ponesimod
- Ravulizumab
- Remdesivir
- Remestemcel-L
- Reslizumab
- Riociguat or its derivatives
- Risdiplam and its salts or derivatives
- Sacubitril or its salts
- Sarilumab
- Satralizumab
- Sebelipase alfa
- Selexipag
- Setmelanotide or its salts
- Sipavibart
- Siltuximab
- Sodium zirconium cyclosilicate
- Somatogon
- Sotrovimab
- Spesolimab
- Tafamidis meglumine
- Taliglucerase alfa
- Teduglutide
- Tesamorelin or its salts or derivatives
- Tezacaftor or its salts
- Tofacitinib or its salts
- Tofersen
- Tolvaptan or its derivatives
- Turoctocog alfa pegol
- Ursodoxicoltaurine and its salts
- Vaborbactam
- Velaglucerase alfa
- Vericiguat or its salts
- Vernakalant or its salts
- Von Willebrand factor, recombinant (vonico g alfa)
- Voretigene neparvovec

Emergency Medicine Agents

- Amrinone and its salts
- Andexanet alfa
- Anti-inhibitor coagulant complex
- Bosentan and its salts and derivatives
- Digoxin immune Fab (ovine)
- Dobutamine and its salts
- Drotrecogin
- Fomepizole and its salts
- Gadopentetate dimeglumine
- Hetastarch and its derivatives
- Landiolol and its salts
- Milrinone and its salts
- Physostigmine salicylate (except preparations for

- oral or topical use only)
- Sodium nitrite (When indicated for administration by injection and

sequential use with sodium thiosulfate for the treatment of acute cyanide poisoning.)

- Sodium nitroprusside and its salts
- Sugammadex
- Urokinase



Endocrine Agents/Endocrine Diagnostic Agents

- Etonogestrel
- except for licensees certified in Prescriptive Authority who have successfully completed the Etonogestrel Extended Release Subdermal Implant Clinician Training Program, and are available to insert the implant

- Gonadotropin, serum (human)
- Histrelin and its salts
- Mepacrine and its salts
- Mecasermin
- Methoxy Polyethelene glycol-epoetin beta
- Metryapone and its salts
- Pegvisomant

- Protirelin TRH analog
- Quinagolide and its salts
- Sermorelin and its salts
- Terlipressin and its salts
- Thyrotropin alfa
- Triiodothyropropionic acid
- Trilostane

Certain Agents Used for 'Emergency Purposes Only'

The following agents are authorized only for in-office emergency use. All other indications for these agents are not allowed:

- Adenosine
- Dopamine
- Procainamide

Agents Dealing with Acute Perinatal Care

- Beractant
- Colfosceril and its derivatives
- Nitric oxide
- Poractant alfa



Obstetrical Agents Out Patient Setting

- Mifepristone - except for NDs who have completed one of the following courses:
- Medical Abortion Training Program- Society of Obstetricians and Gynaecologists of Canada (SOGC)
- Medical Abortion Virtual Course – National Abortion Federation of Canada
- Ritodrine and its salts

Ophthalmic Agents

Agents used for the treatment of iritis or glaucoma agents:

- Aflibercept
- Brimonidine and its salts
- Carbachol
- Cyclopentolate and its salts (parenteral use only)
- Dipivefrin
- Dorzolamide
- Ecothiophate
- Fluocinolone acetonide
- Homatropine and its salts (ophthalmic use or >2mg oral)
- Latanoprost
- Latanoprostene Bunod or its salts or derivatives
- Levobunolol
- Lifitegrast or its salts
- Methazolamide
- Nepafenac
- Ocriplasmin
- Pilocarpine
- Timolol (excluded for ophthalmic use only)
- Unoprostone

Topical corticosteroids:

- Dexamethasone (excluded for ophthalmic use only)
- Prednisolone (excluded for ophthalmic use only)



Miscellaneous ophthalmic preparations:

- Brilliant Blue G or its derivatives
- Bromfenac or its salts
- Pegaptanib
- Trifluridine
- Verteporfin

The following agents are allowed for the treatment of hypotrichosis of the eyelid only:

- Bimatoprost to the maximum strength of 0.03% w/v.
- Bimatoprost otherwise remains excluded for the treatment of intraocular pressure.

Anti-Parkinson Agents

- Apomorphine
- Biperiden and its salts
- Safinamide and its salts
- Tolcapone

Antipsychotic Agents

- Acepromazine and its salts
- Butaperazine and its salts
- Cariprazine and its salts
- Chlorprothixene and its salts
- Mesoridazine and its salts
- Pericyazine and its salts
- Pipotiazine and its salts
- Promazine and its salts
- Remoxipride and its salts
- Thiethylperazine and its salts
- Thioridazine and its salts
- Thiothixene and its salts
- Triflupromazine and its salts
- Trimeprazine and its salts



Antiarrhythmic Agents

- Bretylium tosylate
- Disopyramide and its salts
- Esmolol and its salts
- Flecainide and its salts
- Ibutilide and its salts and derivatives
- Isoproterenol (isoprenaline) and its salts
- Methoxamine and its salts
- Mexiletine and its salts
- Procainamide and its salts
- Quinidine salts
- Sotalol and its salts
- Tocainide and its salts

Antifungal Agents

- Anidulafungin

Antitubercular Agents Used for Other Infections

- Isoniazid

Thrombolytic, Hemostatic and Anti-Platelet Agents

- Alteplase except when given in a dosage of 4mg or less (Alteplase is approved for use by NDs for a maximum dosage of 4 mg)
- Ambrisentan
- Aminocaproic acid
- Aprotinin
- Argatroban and its salts and derivatives
- Bivalirudin
- Catridecacog
- Danaparoid and its salts and derivatives
- Enoxaparin and its salts
- Eptifibatide and its salts
- Idrucizumab
- Reviparin and its salts
- Romiplostim
- Streptokinase/streptodornase
- Tenecteplase and its salts and derivatives
- Tirofiban and its salts and derivatives



Vaccines

- Anthrax Vaccine Adsorbed

Infertility Agents

- Lanreotide
- Lutropin alfa
- Triptorelin or its salts or derivatives
- Urofollitropin

Immunoglobulins

- Cytomegalovirus immune globulins
- Hepatitis B immune globulin
- Immune globulin products
- Rho D immune globulin
- Rabies immune globulin
- Tetanus immune globulin
- Varicella Zoster immune globulin

Not in force until April 1, 2026

Other



- Afoxolaner
- Avilamycin or its salts or derivatives
- Becaplermin
- Benactyzine
- Benoxaprofen
- C1 esterase inhibitor
- Chlormezanone
- Cisapride
- Cobicistat
- Defibrotide or its salts or derivatives
- Dexfenfluramine
- Dichloroacetic acid (DCA)
- Dirlotapide
- Doxapram
- Etranacogene dezaparvec
- Etryptamine and its salts
- Fecal microbiota (Rebyota® ONLY) - INCLUDED FOR Health Canada Approved indications only
- Fidanacogene elaparvovec
- Firocoxib
- Fluralaner
- Gamithromycin
- Histamine (except topical use)
- Ibafloracin
- Ibogaine or its salts or derivatives or analogues
- Imidapril or its salts
- Inebilizumab
- Ingenol mebutate or its derivatives
- Maropitant or its salts
- Medotomidine
- Mephentermine
- Melarsomine or its salts
- Methyprylon
- Metreleptin
- Mitratapide
- Oclacitinib or its salts
- Octatropine methyrbromide
- Oxalinic acid
- Paricalcitol
- Phacetoperane
- Pradofloxacin or their salts or derivatives
- Robenacoxib or its salts
- Sevoflurane
- Terfenadine
- Tepoxalin or its derivatives
- Toceranib or its salts
- Toltrazuril or its salts or derivatives (including Ponazuril)
- Valdecoxib
- Xanthinol nicotinate
- Zilucoplan or its salts
- Zomepirac

Continuation Therapy Only

These drugs are approved for ND use only for continuation of existing prescriptions, and are excluded for all other purposes:

- Asenapine or its salts or derivatives
- Azathioprine
- Bacillus Calmette-Guérin (BCG) (as an antineoplastic agent)
- Brexpiprazole or its salts
- Cariprazine or its salts
- Cenobamate or its salts
- Eslicarbazepine acetate
- Evinacumab
- Lacosamide or its derivatives
- Methotrexate
- Obeticholic acid or its salts
- Olipudase alfa
- Vutrisiran and its salts



Not in force until April 1, 2026